ZVRA vs. TRVI, IXHL, ATOS, CDT, IVA, OGI, ACRV, HOWL, TELO, and VERU
Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Trevi Therapeutics (TRVI), Incannex Healthcare (IXHL), Atossa Therapeutics (ATOS), Conduit Pharmaceuticals (CDT), Inventiva (IVA), Organigram (OGI), Acrivon Therapeutics (ACRV), Werewolf Therapeutics (HOWL), Telomir Pharmaceuticals (TELO), and Veru (VERU). These companies are all part of the "pharmaceutical preparations" industry.
Zevra Therapeutics (NASDAQ:ZVRA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.
Zevra Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
In the previous week, Trevi Therapeutics had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 13 mentions for Trevi Therapeutics and 10 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.85 beat Trevi Therapeutics' score of 0.41 indicating that Zevra Therapeutics is being referred to more favorably in the media.
Trevi Therapeutics has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -181.76%. Trevi Therapeutics' return on equity of -39.54% beat Zevra Therapeutics' return on equity.
35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 27.5% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Zevra Therapeutics presently has a consensus price target of $19.50, indicating a potential upside of 312.26%. Trevi Therapeutics has a consensus price target of $8.50, indicating a potential upside of 206.86%. Given Zevra Therapeutics' higher probable upside, equities research analysts plainly believe Zevra Therapeutics is more favorable than Trevi Therapeutics.
Trevi Therapeutics has lower revenue, but higher earnings than Zevra Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics received 65 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 60.94% of users gave Trevi Therapeutics an outperform vote.
Summary
Zevra Therapeutics and Trevi Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Zevra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevra Therapeutics Competitors List
Related Companies and Tools
